D. Boral Capital notes that Can-Fite BioPharma (CANF) announced that its research on novel anti-cancer drug candidate namodenoson will be featured at the 2025 ASCO Gastrointestinal Cancers Symposium. The upcoming presentation at ASCO “underscores the innovative potential” of namodenoson as both an effective anti-cancer agent and a liver-protective therapy, says the analyst, who argues that namodenoson, with “a compelling long-term case” of complete cancer remission in a Phase 2b trial patient, may represent “a paradigm shift in liver cancer therapeutics.” The firm has a Buy rating and $10 price target on Can-Fite shares.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite’s Namodenoson to be Highlighted for Liver Protection at ASCO Symposium
- Can-Fite BioPharma announces presentation on namodenoson
- Biotech Alert: Searches spiking for these stocks today
- Can-Fite BioPharma’s Namodenoson Shows Promising Cancer Results
- Can-Fite announces 8 year survival for patient in Phase 2 Liver Cancer study